The General Pharmaceutical Council (GPhC) received 21 disclosures from whistleblowers over the last financial year, of which 20 concerned community pharmacy, C+D has learned.
Last month (September 27), the GPhC released its annual whistleblowing report for April 1 2022 to March 31 2023.
The report – which the regulator is legally required to publish – revealed that the GPhC took “regulatory action” on 12 of the 21 disclosures made to it by whistleblowers.
Of the 21 disclosures brought to the pharmacy regulator, five remain under review, three were referred “to an alternative body” but no further action was taken and just one case was closed with no action, according to the report.
Read more: Health secretary alerted as GPhC fails FtP standard for fifth consecutive year
The GPhC also concluded three disclosures raised during the previous reporting period with “no further action”, it said.
The negotiator told C+D yesterday (October 9) that of the 21 disclosures it received, 20 cases concerned community pharmacy and one was about an online pharmacy.
However, the nature of the concerns raised remains unclear.
The report said that “action” taken on concerns raised by whistleblowers included “a full investigation through established fitness-to-practise (FtP) processes”.
If the regulator judges that “follow-up action” is required, this will be taken “through [its] inspection network”, it added.
Read more: An inspector calls: GPhC...
It’s starting to look like somebody’s got a serious vendetta against Future and will stop at nothing to try and destroy his brand and career because the math isn’t mathing and facts just aren’t li...